{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:34:00Z","timestamp":1793666040019,"version":"4.5.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jaip.2022.01.038","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T12:02:22Z","timestamp":1643976142000},"page":"1295-1304.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Evaluation of Combination Therapy With Etanercept and Systemic Corticosteroids for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Multicenter Observational Study"],"prefix":"10.1016","volume":"10","author":[{"given":"Jing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Wei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Bing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ti","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2022.01.038_bib1","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/1346-8138.13430","article-title":"Severe cutaneous adverse drug reactions","volume":"43","author":"Chung","year":"2016","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2022.01.038_bib2","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.ajo.2008.12.040","article-title":"Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset","volume":"147","author":"Araki","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jaip.2022.01.038_bib3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1440-0960.2011.00862.x","article-title":"The management of toxic epidermal necrolysis","volume":"53","author":"Fernando","year":"2012","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaip.2022.01.038_bib4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00000658-198611000-00001","article-title":"Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids","volume":"204","author":"Halebian","year":"1986","journal-title":"Ann Surg"},{"key":"10.1016\/j.jaip.2022.01.038_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/01.iio.0000177430.89645.6d","article-title":"Controversy in the use of high-dose systemic steroids in the acute care of patients with Stevens-Johnson syndrome","volume":"45","author":"Hynes","year":"2005","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.jaip.2022.01.038_bib6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jaad.2013.04.007","article-title":"Methylprednisolone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis: clinical evaluation and analysis of biomarkers","volume":"69","author":"Hirahara","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.01.038_bib7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3904\/kjim.2012.27.2.203","article-title":"Causes and treatment outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in 82 adult patients","volume":"27","author":"Kim","year":"2012","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.jaip.2022.01.038_bib8","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ajo.2009.09.017","article-title":"Systemic and local management at the onset of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications","volume":"149","author":"Sotozono","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jaip.2022.01.038_bib9","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/ijd.12118","article-title":"Severe cutaneous adverse reactions in a local hospital setting: a 5-year retrospective study","volume":"53","author":"Su","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2022.01.038_bib10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.alit.2015.09.001","article-title":"Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients: treatment and outcome","volume":"65","author":"Yamane","year":"2016","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2022.01.038_bib11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2012.10965.x","article-title":"The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"167","author":"Huang","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2022.01.038_bib12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.clim.2009.09.006","article-title":"Exposure of NK cells to intravenous immunoglobulin induces IFN\u03b3 release and degranulation but inhibits their cytotoxic activity","volume":"133","author":"Jacobi","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaip.2022.01.038_bib13","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1542\/peds.104.S2.367b","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with intravenous immunoglobulin","volume":"104","author":"Sicherer","year":"1999","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaip.2022.01.038_bib14","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"153","author":"Zimmermann","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2022.01.038_bib16","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2340\/00015555-0462","article-title":"Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis","volume":"88","author":"Wojtkiewicz","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaip.2022.01.038_bib17","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nature Med"},{"key":"10.1016\/j.jaip.2022.01.038_bib18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jaci.2004.04.034","article-title":"Involvement of CCL27-CCR10 interactions in drug-induced cutaneous reactions","volume":"114","author":"Tapia","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.01.038_bib19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1067\/mai.2002.120563","article-title":"Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity","volume":"109","author":"Posadas","year":"2002","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.01.038_bib20","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaip.2022.01.038_bib21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41584-018-0133-2","article-title":"New therapeutic strategies in systemic lupus erythematosus management","volume":"15","author":"Gatto","year":"2019","journal-title":"Nature Rev Rheumatol"},{"key":"10.1016\/j.jaip.2022.01.038_bib22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/ACI.0000000000000493","article-title":"Strategies to reduce corticosteroid-related adverse events in asthma","volume":"19","author":"Heffler","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.01.038_bib23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0049-0172(99)80034-1","article-title":"Methotrexate and leflunomide: biochemicalbasis for combination therapy in the treatment of rheumatoid arthritis","volume":"29","author":"Kremer","year":"1999","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaip.2022.01.038_bib24","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jaad.2020.08.122","article-title":"Treating toxic epidermal necrolysis with systemic immunomodulating therapies: a systematic review and network meta-analysis","volume":"84","author":"Tsai","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.01.038_bib25","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2022.01.038_bib26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A\u00a0method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaip.2022.01.038_bib27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tox.2004.12.022","article-title":"Clinical heterogeneity of drug hypersensitivity","volume":"209","author":"Roujeau","year":"2005","journal-title":"Toxicology"},{"key":"10.1016\/j.jaip.2022.01.038_bib28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaip.2022.01.038_bib29","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Fouchard","year":"2000","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2022.01.038_bib30","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jaad.2020.08.122","article-title":"Treating toxic epidermal necrolysis with systemic immunomodulating therapies: a systematic review and network meta-analysis","volume":"84","author":"Tsai","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.01.038_bib31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/oxfordjournals.aje.a114083","article-title":"Another shortcut method for calculating the confidence interval of a Poisson variable (or of a standardized mortality ratio)","volume":"122","author":"Ury","year":"1985","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jaip.2022.01.038_bib32","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.immuni.2008.04.020","article-title":"Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity","volume":"28","author":"Chessman","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.jaip.2022.01.038_bib33","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.jaci.2011.12.990","article-title":"Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome","volume":"129","author":"Wei","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.01.038_bib34","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jaci.2013.04.036","article-title":"A new nucleic acid\u2013based agent inhibits cytotoxic T lymphocyte\u2013mediated immune disorders","volume":"132","author":"Wang","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.01.038_bib35","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1365-2133.1996.tb06976.x","article-title":"Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis","volume":"134","author":"Paul","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2022.01.038_bib36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2133.2005.06721.x","article-title":"Toxic epidermal necrolysis: current evidence, practical management and future directions","volume":"153","author":"Chave","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2022.01.038_bib37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study","volume":"58","author":"Schneck","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.01.038_bib38","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/ijd.15586","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis in a referral center in Taiwan","volume":"60","author":"Hsu","year":"2021","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2022.01.038_bib43","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/ds.ds_24_20","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis related to immune checkpoint inhibitors: Two cases and literature review","volume":"38","author":"Hsu","year":"2020","journal-title":"Dermatologica Sinica"},{"key":"10.1016\/j.jaip.2022.01.038_bib39","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev.immunol.18.1.309","article-title":"Glucocorticoids in T cell development and function","volume":"18","author":"Ashwell","year":"2000","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaip.2022.01.038_bib40","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1042\/cs0940557","article-title":"Anti-inflammatory actions of glucocorticoids: molecular mechanisms","volume":"94","author":"Barnes","year":"1998","journal-title":"Clinical science"},{"key":"10.1016\/j.jaip.2022.01.038_bib41","doi-asserted-by":"crossref","first-page":"E22","DOI":"10.12788\/cutis.0288","article-title":"Efficacy of Etanercept in the Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis","volume":"107","author":"Dreyer","year":"2021","journal-title":"Cutis"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822001180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822001180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:33:22Z","timestamp":1761975202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219822001180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S2213219822001180"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2022.01.038","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of Combination Therapy With Etanercept and Systemic Corticosteroids for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Multicenter Observational Study","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2022.01.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}